Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck (E1304): a trial of the Eastern Cooperative Oncology Group.

Gilbert J, Lee JW, Argiris A, Haigentz M, Feldman LE, Jang M, Arun P, Van Waes C, Forastiere AA
Head Neck. 2013 35 (7): 942-8

PMID: 22791234 · PMCID: PMC3689864 · DOI:10.1002/hed.23046

MeSH Terms (20)

Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols Boronic Acids Bortezomib Camptothecin Carcinoma, Squamous Cell Cytokines Disease Progression Female Head and Neck Neoplasms Humans Irinotecan Male Middle Aged NF-kappa B Pyrazines Squamous Cell Carcinoma of Head and Neck Treatment Outcome

Connections (1)

This publication is referenced by other Labnodes entities:

Links